CRL Q2 Deep Dive: Flat Sales and Margin Pressures Offset by Demand Stabilization and Raised Outlook

Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $1.03 billion. Its non-GAAP profit of $3.12 per share was 24.6% above analysts’ consensus estimates.

Is now the time to buy CRL? Find out in our full research report (it’s free).

StockStory’s Take

Charles River Laboratories’ second quarter results were met with a significant negative market reaction, despite the company’s revenue and non-GAAP profit both topping Wall Street expectations. Management attributed the quarterly outperformance primarily to stronger-than-anticipated activity in its Discovery and Safety Assessment (DSA) business, driven by bookings strength from the prior quarter and favorable foreign exchange movements. CEO James Foster highlighted stabilization in the demand environment, noting that “global biopharmaceutical demand trends appear to have bottomed, and we believe they are beginning to slowly move upward.” However, the company acknowledged that operating margin contraction and persistent uncertainties in biotech funding and client spending patterns remain ongoing challenges.

Looking ahead, Charles River Laboratories raised its full-year non-GAAP earnings guidance, reflecting confidence in continued operational execution and gradual demand recovery across core segments. Management’s outlook is underpinned by expectations for steady DSA demand, incremental cost savings, and selective hiring to support anticipated growth. CFO Flavia Pease emphasized that the updated guidance does not require a return to higher historical levels of bookings, stating, “We’re not expecting book-to-bill to return to above 1x to meet our guidance.” The company is also monitoring potential headwinds from industry regulation, funding shifts, and tariff impacts, but currently views these risks as manageable within its updated outlook.

Key Insights from Management’s Remarks

Management attributed the quarter’s results to a surge in DSA bookings from prior quarters, stable pricing, and operational efficiencies, while flagging one-off gains in the CDMO segment and continued caution around client funding dynamics.

• DSA segment drives performance: The Discovery and Safety Assessment business benefited from a significant lift in bookings recorded in the previous quarter, enabling higher-than-expected revenue conversion in Q2. Management noted this was due to “pent-up demand by our clients” following earlier project delays.
• Stable pricing environment: CEO James Foster and CFO Flavia Pease described pricing as stable, with mix favorability in the DSA segment enhancing price realization. Management clarified that while some competitors have used aggressive pricing tactics, Charles River’s focus remains on scientific quality and client relationships.
• CDMO outperformance is temporary: The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) business saw elevated revenue and margins due to the wind-down of a commercial client relationship and associated payments. Pease warned that these contributions will not recur in the second half, creating a known headwind.
• Cost savings and restructuring: The ongoing restructuring program is on track to deliver over $175 million in annualized cost savings for 2025, supporting margins amid flat revenue trends. Management is reinvesting some of these savings into targeted DSA hiring to support future demand.
• NAMs portfolio expansion: Charles River continues to expand its New Approach Methods (NAMs)—non-animal testing capabilities—highlighting projects such as in vitro liver-on-a-chip assays and increased client interest. Management views this as a long-term transition and a future growth driver.

Drivers of Future Performance

Charles River Laboratories expects stabilized demand and incremental cost savings to shape its outlook, but anticipates margin headwinds from increased hiring and one-off CDMO revenue lapses.

• Steady DSA demand, but not linear: Management anticipates a gradual recovery in DSA bookings, with current book-to-bill ratios in the 0.8x–0.93x range considered sufficient for guidance. CEO Foster stressed that a “steady improvement” in demand is expected, but not a straight-line recovery, as smaller biotechs remain cash constrained.
• Margin pressures expected: The company flagged several second-half headwinds, including higher DSA staffing costs, the end of a major CDMO commercial relationship, and timing of annual merit increases. Pease said these factors will result in consolidated operating margins below first-half levels despite ongoing cost savings.
• Regulatory and funding risks monitored: Management acknowledged potential risks from U.S. drug pricing reforms, NIH funding uncertainties, and tariffs. While these have had minimal impact to date, Foster cautioned that “if the shoe does fall,” these could become more significant in 2026.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will be watching (1) whether DSA segment demand continues its upward trajectory and bookings stabilize, (2) the impact of margin headwinds from cost structure changes, especially as temporary CDMO revenue rolls off, and (3) ongoing progress in expanding the NAMs portfolio. Additionally, clarity on regulatory risks and biotech funding trends will be important markers for sustained recovery.

Charles River Laboratories currently trades at $148.93, down from $167.49 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.